Contrasting IMV (OTCMKTS:IMVIQ) and NexImmune (NASDAQ:NEXI)

Risk and Volatility

IMV has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.

Valuation and Earnings

This table compares IMV and NexImmune”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMV	$330,000.00	0.00	-$37.99 million	($4.59)	N/A
NexImmune	N/A	N/A	-$32.34 million	($18.29)	0.00

NexImmune has lower revenue, but higher earnings than IMV. NexImmune is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.9% of NexImmune shares are held by institutional investors. 0.3% of IMV shares are held by company insiders. Comparatively, 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares IMV and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMV	N/A	N/A	N/A
NexImmune	N/A	-534.32%	-213.72%

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.